Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inhaled Mometasone to Promote Reduction in Vasoocclusive Events

NCT02061202 is registered in ClinicalTrials.gov with Jeffrey Glassberg as lead sponsor.

NCT NCT02061202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02061202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inhaled Mometasone to Promote Reduction in Vasoocclusive Events
Lead sponsor
Jeffrey Glassberg
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2014
Completion date
November 30, 2017
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease